{"title":"Efficacy and Safety of Infliximab for Ankylosing Spondylitis in Japanese Patients: A Retrospective Study of 11 Cases.","authors":"Yusuke Kubo, Masanobu Ohishi, Yasuharu Nakashima, Ken Okazaki, Jun-ichi Fukushi, Akiko Oyamada, Yukihide Iwamoto","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Tumor necrosis factor inhibitors (TNFi) such as infliximab (IFX) and adalimumab have been shown to be efficacious not only for rheumatoid arthritis but also for Ankylosing Spondylitis (AS). However, only a limited number of reports regarding the effect of TNFi on AS in Japanese population have been published.</p><p><strong>Materials and methods: </strong>We retrospectively evaluated all 11 patients (8 males and 3 females) with AS who were treated with IFX.</p><p><strong>Results: </strong>After a mean follow-up period of 19 months, the mean BASDAI decreased from 4.7 ± 2.2 to 1.7 ± 1.2 and the serum CRP level decreased from 1.62 ± 1.94 mg/dl to 0.23 ± 0.45 mg/dl. There was no case of serious infection or anaphylaxis.</p><p><strong>Conclusions: </strong>Our results indicate that IFX is efficacious and safe for AS in Japanese patients.</p>","PeriodicalId":12665,"journal":{"name":"Fukuoka igaku zasshi = Hukuoka acta medica","volume":"106 12","pages":"316-22"},"PeriodicalIF":0.0000,"publicationDate":"2015-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fukuoka igaku zasshi = Hukuoka acta medica","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Tumor necrosis factor inhibitors (TNFi) such as infliximab (IFX) and adalimumab have been shown to be efficacious not only for rheumatoid arthritis but also for Ankylosing Spondylitis (AS). However, only a limited number of reports regarding the effect of TNFi on AS in Japanese population have been published.
Materials and methods: We retrospectively evaluated all 11 patients (8 males and 3 females) with AS who were treated with IFX.
Results: After a mean follow-up period of 19 months, the mean BASDAI decreased from 4.7 ± 2.2 to 1.7 ± 1.2 and the serum CRP level decreased from 1.62 ± 1.94 mg/dl to 0.23 ± 0.45 mg/dl. There was no case of serious infection or anaphylaxis.
Conclusions: Our results indicate that IFX is efficacious and safe for AS in Japanese patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
